Lenalidomide (Revlimid)

DRUG2 trials

Sponsors

NYU Langone Health, Second Affiliated Hospital, School of Medicine, Zhejiang University

Conditions

Multiple MyelomaSolitary Plasmacytoma

Phase 2

Combination of Revlimid, Melphalan and Dexamethasone as First Line Treatment for Multiple Myeloma

TerminatedNCT00843310

NYU Langone HealthMultiple Myeloma

Start: 2008-11-30End: 2011-10-31Updated: 2017-07-19

SBRT Plus Lenalidomide for Solitary Plasmacytoma: Phase II Trial

RecruitingNCT06863584

Second Affiliated Hospital, School of Medicine, Zhejiang UniversitySolitary Plasmacytoma

Start: 2025-02-10End: 2032-03-01Target: 41Updated: 2025-03-07